Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX)
Post Marketing Study in Haemophilia B Patients Using Nonafact® 100 IU/ml Powder and Solvent for Solution for Injection(Human Coagulation Factor IX)(Human Plasma Derived Factor IX Product, Freeze Dried)
Sponsor: Prothya Biosolutions
A PHASE4 clinical study on Hemophilia B, this trial is completed. The trial is conducted by Prothya Biosolutions and has accumulated 7 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2022 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jan 2022 [monthly]
Completed PHASE4
-
Jul 2019 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 2 earlier versions
-
Jun 2018 — Jul 2019 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
May 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Prothya Biosolutions
For direct contact, visit the study record on ClinicalTrials.gov .